Podcast

Speaking Out About Breast Implant-Associated Cancer

Author(s):

Kristie L. Kahl

In this episode of CURE® Talks Cancer, we spoke with an advocate who is raising awareness around the recent controversy surrounding a certain type of breast implant that is causing a rare type of lymphoma.

Imagine overcoming a breast cancer diagnosis and its treatment, yet in choosing reconstructive surgery with textured implants, finding out you may be at risk for a rare type of lymphoma.

Renee Ridgeley found herself in that exact situation.

Following the recent controversy with a Food and Drug Administration panel not banning these implants that are to blame for causing breast implant-associated anaplastic large-cell lymphoma, many women are speaking out about the issue.

In this week’s CURE® Talks Cancer podcast, we spoke with the patient advocate about her own experience and how women can learn more about their reconstruction options.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Image of woman with brown hair.
Image of a woman wearing a headband and glasses
Image of doctor.
Image of woman.
Image of Doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image od grey haired Doctor.
Related Content
The first patient has been dosed in a phase 1/2 trial investigating treatment with AP402, a T-cell engager, for patients with HER2-positive cancers: stock.adobe.com.
April 23rd 2025

First Patient Dosed with AP402 in a Trial for HER2 Advanced Tumors

Spencer Feldman
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
The combination of Enhertu plus Perjeta showed improvement in progression-free survival versus standard treatment among patients with HER2-positive metastatic breast cancer.
April 21st 2025

Enhertu Combo Improves Progression in HER2+ Metastatic Breast Cancer

Ryan Scott
Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive metastatic breast cancer.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Dr. Rugo has led key breast cancer therapy trials and exudes a passion for serving patients.
April 18th 2025

Renowned Breast Cancer Physician-Scientist Dr. Hope S. Rugo to Lead City of Hope’s Women’s Cancers Program

City of Hope
Dr. Rugo has led key breast cancer therapy trials and exudes a passion for serving patients.
Illustration of Debbie.
April 17th 2025

How I Manage When My Social Media Friends with Cancer Disappear

Debbie Legault
I stay in the cancer social media world because it helps me cope, even when friends disappear and I’m left wondering if they’re resting, retreating or gone.